Nucleus RadioPharma News and Resources

Nucleus RadioPharma to manufacture the cancer drug 67Cu-SAR-bisPSMA for Clarity Pharmaceuticals, a clinical-stage company focusing on radiopharmaceuticals. Under the agreement, Nucleus RadioPharma, a contract development and manufacturing organisation (CDMO), will produce the drug at its state-of-the-art facility in Rochester, Minnesota,

Nucleus RadioPharma has announced plans to build two new facilities in Mesa, Arizona, and Springhouse, Pennsylvania, totaling over 100,000 square feet. These sites will integrate research, development, and commercial production, providing key advantages for the radiopharmaceutical industry. The expansion seeks

Nucleus RadioPharma, a company specialising in the development and manufacturing of radiopharmaceuticals, has announced the successful closure of a Series A extension funding round. The investment was led by AstraZeneca, a new investor, joining forces with existing stakeholders such as